New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 31, 2013
04:55 EDTATHX, ATHX, ATHXAthersys management to meet with Maxim
Meetings to be held in London on November 5-6 hosted by Maxim.
News For ATHX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 29, 2015
09:19 EDTATHXAthersys to hold a conference call
Chairman & CEO Van Bokkelen discusses the recently announced interim results of the company's exploratory Phase 2 clinical study of the intravenous administration of MultiStem(R) cell therapy on a conference call to be held on April 29 at 2 pm. Webcast Link
April 22, 2015
05:48 EDTATHXStocks with implied volatility movement; CSX ATHX
Stocks with implied volatility movement; CSX (CSX) 40, Athersys (ATHX) 151 according to iVolatility.
April 21, 2015
09:45 EDTATHXMaxim still bullish on Athersys, says data show 'strong signal'
Maxim analyst Jason Kolbert told investors today that he remains bullish on Athersys after the company announced Friday morning its stroke trial missed the primary and secondary endpoints. Kolbert says the data show MultiStem appears to be able to extend the treatment window in stroke from a few hours to 36 hours, which he calls "dramatic." He views the data as showing a "strong signal," and added "it seems that no one wants to hear or look" at it. The analyst expects Athersys to announce plans to move forward in a Phase IIb/III global trial in the U.S., Europe and Japan. He pointed out that Maxim hopes to announce next week a series of conference calls with Athersys management and experts. Kolbert kept a Buy rating on Athersys with a $9 price target. The stock is trading down 3c to $1.32 in early trading.
April 20, 2015
11:53 EDTATHXPiper Jaffray biotech analysts hold an analyst/industry conference call
Biotech Analysts Tenthoff and Adler, along with Dr. Stanley Tuhrim, discuss Athersys' MultiStem ischemic stroke results on an Analyst/Industry conference call to be held on April 20 at 1 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use